![Brian Hubbard](data:image/svg+xml,<svg xmlns="http://www.w3.org/2000/svg" width="16" height="16" fill="%231b1b1b" class="bi bi-person-fill" viewBox="0 0 16 16"><path d="M3 14s-1 0-1-1 1-4 6-4 6 3 6 4-1 1-1 1zm5-6a3 3 0 1 0 0-6 3 3 0 0 0 0 6"/></svg>)
Brian Hubbard
Private Equity Investor bei
Sprout Bioventures
Profil
Brian Hubbard currently works at Sprout Bioventures, as Partner from 2018.
Dr. Hubbard also formerly worked at Dogma Therapeutics, Inc., as Chief Executive officer from 2015 to 2020, Novartis AG, as Director from 2002 to 2008, The Broad Institute, Inc., as Director from 2011 to 2015, and Merck Global Health Innovation LLC, as Sr. Director from 2008 to 2011.
Dr. Hubbard received his undergraduate degree in 1994 from The College of William & Mary, doctorate degree from the University of Illinois, and graduate degree from Harvard Medical School.
Aktive Positionen von Brian Hubbard
| Unternehmen | Position | Beginn |
|---|---|---|
Sprout Bioventures
 Sprout Bioventures Investment ManagersFinance Sprout Bioventures invests in companies located in the United States. The firm focuses on Biotechnology Research sectors. It participates in early stage transactions. | Private Equity Investor | 01.01.2018 |
Ehemalige bekannte Positionen von Brian Hubbard
| Unternehmen | Position | Ende |
|---|---|---|
Dogma Therapeutics, Inc.
 Dogma Therapeutics, Inc. Pharmaceuticals: MajorHealth Technology Developing oral PCSK9 inhibitors to treat high cholesterol and cardiovascular disease | Vorstandsvorsitzender | 02.08.2020 |
The Broad Institute, Inc.
 The Broad Institute, Inc. BiotechnologyHealth Technology Engages in research and development in bio medicals to cure infectious disease, cancer, psychiatric research and cardiovascular diseases | Direktor der Forschung - Eigenkapital | 02.08.2015 |
Merck Global Health Innovation LLC
 Merck Global Health Innovation LLC Investment ManagersFinance Merck Global Health invests in companies located across the globe primarily in North America and Europe. The firm targets companies operating in the fields of drug discovery & clinical development, manufacturing, supply chain & IT, access to medicine & patient support and real world evidence generation It provides financing for early and growth stage capital requirements with an investment size of USD 5 - 10 million. | Direktor der Forschung - Eigenkapital | 02.09.2011 |
| NOVARTIS AG | Direktor der Forschung - Eigenkapital | 02.01.2008 |
Ausbildung von Brian Hubbard
Erfahrungen
Besetzte Positionen
Aktive
Inaktive
Börsennotierte Unternehmen
Private Unternehmen
Beziehungen
88
Beziehungen ersten Grades
8
Unternehmen ersten Grades
Herr
Frau
Aufsichtsräte
Führungskräfte
Unternehmensverbindungen
| Private Unternehmen | 8 |
|---|---|
Novartis AG
 Novartis AG Pharmaceuticals: MajorHealth Technology Manufactures and markets health care and nutritional products | Health Technology |
The College of William & Mary
 The College of William & Mary Other Consumer ServicesConsumer Services Functions as a College/University | Consumer Services |
University of Illinois
 University of Illinois Other Consumer ServicesConsumer Services Functions as a College/University | Consumer Services |
The Broad Institute, Inc.
The Broad Institute, Inc. BiotechnologyHealth Technology Engages in research and development in bio medicals to cure infectious disease, cancer, psychiatric research and cardiovascular diseases | Health Technology |
Harvard Medical School
 Harvard Medical School Other Consumer ServicesConsumer Services Functions as a College/University | Consumer Services |
Merck Global Health Innovation LLC
Merck Global Health Innovation LLC Investment ManagersFinance Merck Global Health invests in companies located across the globe primarily in North America and Europe. The firm targets companies operating in the fields of drug discovery & clinical development, manufacturing, supply chain & IT, access to medicine & patient support and real world evidence generation It provides financing for early and growth stage capital requirements with an investment size of USD 5 - 10 million. | Finance |
Sprout Bioventures
Sprout Bioventures Investment ManagersFinance Sprout Bioventures invests in companies located in the United States. The firm focuses on Biotechnology Research sectors. It participates in early stage transactions. | Finance |
Dogma Therapeutics, Inc.
Dogma Therapeutics, Inc. Pharmaceuticals: MajorHealth Technology Developing oral PCSK9 inhibitors to treat high cholesterol and cardiovascular disease | Health Technology |
